APA (7th ed.) Citation

Ugurel, S., Schadendorf, D., Sucker, A., & Paschen, A. (2020). Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Annals of urologic oncology, 31(1), . https://doi.org/10.1016/j.annonc.2019.09.005

Chicago Style (17th ed.) Citation

Ugurel, Selma, Dirk Schadendorf, Antje Sucker, and Annette Paschen. "Elevated Baseline Serum PD-1 or PD-L1 Predicts Poor Outcome of PD-1 Inhibition Therapy in Metastatic Melanoma." Annals of Urologic Oncology 31, no. 1 (2020). https://doi.org/10.1016/j.annonc.2019.09.005.

MLA (9th ed.) Citation

Ugurel, Selma, et al. "Elevated Baseline Serum PD-1 or PD-L1 Predicts Poor Outcome of PD-1 Inhibition Therapy in Metastatic Melanoma." Annals of Urologic Oncology, vol. 31, no. 1, 2020, https://doi.org/10.1016/j.annonc.2019.09.005.